Proteomics International Laboratories Ltd
QQ Block, QEII Medical Centre, 6
Verdun Street
Nedlands
West Australia
6009
Website: http://www.proteomics.com.au/
About Proteomics International Laboratories Ltd
Proteomics International is a medical technology company focused on proteomics – the industrial scale study of the structure and function of proteins. In the last few years, proteins have become the drug class of choice for the pharmaceutical industry because of their intimate role in biological systems. Thus proteomics technology is now playing a key role in understanding disease, from finding new diagnostic biomarkers to determining drug targets, and discovering new biopharmaceutical drugs.Established in 2001, Proteomics International is recognised as a global leader in the field of proteomics. It operates from state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia.
YEAR FOUNDED:
2001
LEADERSHIP:
Founder: Richard John Lipscombe
JOBS:
Please click here for Proteomics International job opportunities.
6 articles about Proteomics International Laboratories Ltd
-
World-first predictive test for Diabetic Kidney Disease could save $384 billion over 10 years
6/25/2021
Proteomics International Laboratories Ltd announces testing for diabetic kidney disease with the PromarkerD prognostic blood test could save US payers almost USD400 billion over 10 years, research suggests.
-
PromarkerD features at American Diabetes Association 79th Scientific Sessions saying diabetics deserve to know their future kidney disease status
6/7/2019
Proteomics International meeting with US tier 1 national diagnostic groups to expand global roll-out of PromarkerD including EU and Mexico
-
Proteomics International and PromarkerD at BIO 2019 saying 30 million diabetics in US deserve to know their future kidney disease status
6/3/2019
PromarkerD world's leading diagnostic test for diabetic kidney disease says Frost & Sullivan industry report 'Biomarkers Enabling Diabetes and Obesity Management'
-
Proteomics International Announces Strategic Alliance and Investment in CPR Pharma Services
2/12/2018
This alliance will see Proteomics International applying its Promarker discovery platform to formulate a new series of predictive diagnostics and analytical services capabilities in compliment to CPR's position as an APAC-based leader in the provision of clinical services and laboratory testing in clinical trials.
-
Dimerix and Proteomics Partner to Improve Treatment of Chronic Kidney Disease
12/14/2017
Proteomics International and Dimerix will evaluate the performance of PromarkerD alongside DMX-200 in early phase clinical trials for chronic kidney disease.
-
Proteomics International Laboratories Ltd Release: Clinical Validation Results Confirm Promarkerd Can Predict Diabetic Kidney Disease Better Than Any Current Measure
6/12/2017